Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to $694.1 million.

  • Arrowhead Pharmaceuticals' Total Non-Current Liabilities fell 1965.62% to $694.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $694.1 million, marking a year-over-year decrease of 1965.62%. This contributed to the annual value of $686.4 million for FY2025, which is 1882.5% down from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Total Non-Current Liabilities is $694.1 million, which was down 1965.62% from $686.4 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $863.9 million in Q4 2024 and a low of $102.6 million during Q2 2021
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $373.0 million (2022), whereas its average is $400.6 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Total Non-Current Liabilities soared by 91601.45% in 2021 and then crashed by 2193.98% in 2022.
  • Arrowhead Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $128.9 million in 2021, then surged by 189.35% to $373.1 million in 2022, then rose by 4.22% to $388.8 million in 2023, then soared by 122.16% to $863.9 million in 2024, then dropped by 19.66% to $694.1 million in 2025.
  • Its Total Non-Current Liabilities was $694.1 million in Q4 2025, compared to $686.4 million in Q3 2025 and $666.3 million in Q2 2025.